Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)

References

• de Graaf J, Veerkamp MJ, Stalenhoef AF. Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J R Soc Med 2002;95(Suppl 42):46–53
   Google Scholar
• Bredie SJ, Tack CJ, Smits P, et al. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler Thromb Vasc Biol 1997;17:1465–71
   PubMed Web of Science ®Google Scholar
• Bredie SJ, Demacker PN, Stalenhoef AF. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur J Clin Invest 1997;27:802–11
   Google Scholar
• de Graaf J, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol 1998;9:189–96
   PubMed Web of Science ®Google Scholar
• Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004;109:2980–5
   PubMed Web of Science ®Google Scholar
• Stroes E, de Bruin T, de Valk H, et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc Res 1997;36:445–52
   PubMed Web of Science ®Google Scholar
• Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899–906
   Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712–9
   PubMed Web of Science ®Google Scholar
• Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004;95:217–23
   PubMed Web of Science ®Google Scholar
• Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000;36:617–21
   PubMed Web of Science ®Google Scholar
• O’driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95: 1126–31
   Google Scholar
• Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002;54:395–9
   PubMed Web of Science ®Google Scholar
• Perticone F, Ceravolo R, Maio R, et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis 2000;152:511–8
   PubMed Web of Science ®Google Scholar
• Sakabe K, Fukuda N, Wakayama K, et al. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. Int J Cardiol 2004;94:111–7
   PubMed Web of Science ®Google Scholar
• Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77:37–40
   Google Scholar
• Wassmann S, Ribaudo N, Faul A, et al. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels < 130 mg/dL. Am J Cardiol 2004;93:84–8
   PubMed Web of Science ®Google Scholar
• Sheu WH, Juang BL, Chen YT, et al. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 1999;22:1224–5
   PubMed Web of Science ®Google Scholar
• van de Ree MA, Huisman MV, de Man FH, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001;52:299–305
   PubMed Web of Science ®Google Scholar
• van Etten RW, de Koning EJ, Honing ML, et al. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002;22:799–804
   PubMed Web of Science ®Google Scholar
• van Venrooij FV, van de Ree MA, Bots ML, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002;25:1211–6
   PubMed Web of Science ®Google Scholar
• Paniagua JA, Lopez-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 2002;51:2596–603
   PubMed Web of Science ®Google Scholar
• Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002;16:92–102
   PubMed Web of Science ®Google Scholar
• Veerkamp MJ, de Graaf J, Stalenhoef AF. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2005;25:1026–31
   PubMed Web of Science ®Google Scholar
• Bijlstra PJ, den Arend JA, Lutterman JA, et al. Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans. Diabetologia 1996;39:1562–8
   PubMed Web of Science ®Google Scholar
• Bijlstra PJ, Lutterman JA, Russel FG, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996;39:1083–90
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111–5
   PubMed Web of Science ®Google Scholar
• Demacker PN, Hijmans AG, Vos-Janssen HE, et al. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 1980;26:1775–9
   Google Scholar
• van Tits LJ, van Himbergen TM, Lemmers HL, et al. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2005;Jul 7; [Epub ahead of print; doi:10.1016/j.atherosclerosis.2005.06.006]
   Google Scholar
• Demacker PN, Veerkamp MJ, Bredie SJ, et al. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis 2000;153:483–90
   PubMed Web of Science ®Google Scholar
• de Galan BE, Tack CJ, Lenders JW, et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002;51:790–6
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9
   PubMed Web of Science ®Google Scholar
• Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700–7
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376–9
   PubMed Web of Science ®Google Scholar
• Lu TM, Ding YA, Leu HB, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hyper-cholesterolemia. Am J Cardiol 2004;94:157–61
   PubMed Web of Science ®Google Scholar
• Parnell MM, Chin-Dusting JP, Starr J, et al. Low-dose atorvastatin therapy does not augment endothelial function in active hyper-cholesterolaemic males. Br J Clin Pharmacol 2003;55:212–5
   PubMed Web of Science ®Google Scholar
• Economides PA, Caselli A, Tiani E, et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004;89:740–7
   PubMed Web of Science ®Google Scholar
• ter Avest E, Holewijn S, Stalenhoef AF, et al. Variation in noninvasive measurements of vascular function in healthy volunteers during daytime. Clin Sci (Lond) 2005;108:425–31
   PubMed Web of Science ®Google Scholar
• Thijssen DH, Bleeker MW, Smits P, et al. Reproducibility of blood flow and post-occlusive reactive hyperaemia as measured by venous occlusion plethysmography. Clin Sci (Lond) 2005;108:151–7
   PubMed Web of Science ®Google Scholar
• Carlsson I, Sollevi A, Wennmalm A. The role of myogenic relaxation, adenosine and prostaglandins in human forearm reactive hyperaemia. J Physiol 1987;389:147–61
   Google Scholar
• Monnink SH, van Haelst PL, van Boven AJ, et al. Endothelial dysfunction in patients with coronary artery disease: a comparison of three frequently reported tests. J Investig Med 2002; 50:19–24
   PubMed Web of Science ®Google Scholar
• Henry RM, Ferreira I, Kostense PJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis 2004;174:49–56
   PubMed Web of Science ®Google Scholar
• Hijmering ML, Stroes ES, Pasterkamp G, et al. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 2001;157:369–73
   PubMed Web of Science ®Google Scholar
• Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003;92:10J–17
   Google Scholar
• Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 1999;353:1789–2
   PubMed Web of Science ®Google Scholar